Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 7/20 | 0.88 |
| ▸ | PTGS2 known ✓ | P35354 | 6/20 | 0.88 |
| ▸ | MAPT | P10636 | 4/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.88 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.88 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 2/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.88 |
| ▸ | RECQL | P46063 | 1/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.88 |
| ▸ | HPGD | P15428 | 1/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.88 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.88 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.88 |
| ▸ | THPO | P40225 | 1/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.88 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketoprofen SCHEMBL27834432 | 0.94 | PTGS1 (0.88) | PTGS1PTGS2MAPTALDH1A1CXCR1 | |
| Ketoprofen SCHEMBL8577572 | 0.94 | PTGS1 (1.00) | PTGS1PTGS2MAPTALDH1A1CXCR1 | |
| Ketoprofen SCHEMBL8754790 | 0.94 | PTGS1 (1.00) | PTGS1PTGS2MAPTALDH1A1CXCR1 | |
| Dexketoprofen SCHEMBL66987 | 0.94 | PTGS1 (1.00) | PTGS1PTGS2MAPTALDH1A1CXCR1 | |
| Ketoprofen SCHEMBL3843886 | 0.94 | PTGS1 (1.00) | PTGS1PTGS2MAPTALDH1A1CXCR1 | |
| Dexketoprofen SCHEMBL29396875 | 0.94 | PTGS1 (1.00) | PTGS1PTGS2MAPTALDH1A1CXCR1 | |
| R-Ketoprofen SCHEMBL29353694 | 0.94 | PTGS1 (1.00) | PTGS1PTGS2MAPTALDH1A1CXCR1 | |
| R-Ketoprofen SCHEMBL195303 | 0.94 | PTGS1 (1.00) | PTGS1PTGS2MAPTALDH1A1CXCR1 | |
| Ketoprofen SCHEMBL16757741 | 0.94 | PTGS1 (1.00) | PTGS1PTGS2MAPTALDH1A1CXCR1 | |
| Ketoprofen SCHEMBL679920 | 0.94 | PTGS1 (1.00) | PTGS1PTGS2MAPTALDH1A1CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989496-B2 | Transdermal delivery of ketoprofen polar derivatives | NOVEN PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | claimed |
| EP-2089007-A2 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES | Noven Pharmaceuticals, INC. (US) | 2009-08-19 | — | — | EP | claimed |
| US-20090062394-A1 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES | NOVEN PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | claimed |
| WO-2008057780-A2 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES | NOVEN PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| US-20110263705-A1 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATES | NOVEN PHARMACEUTICALS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7989496-B2 | Transdermal delivery of ketoprofen polar derivatives | NOVEN PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2089007-A2 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES | Noven Pharmaceuticals, INC. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090062394-A1 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES | NOVEN PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| WO-2008057780-A2 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES | NOVEN PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-5108916-A | Racemic mixtures | RHONE-POULENC RORER, S.A. (FR) | 1992-04-28 | — | — | US | disclosed |
| EP-0407033-A2 | Lipase and isozymes, notably of Candida rugosa, and their use | RHONE-POULENC INC. (US) | 1991-01-09 | — | — | EP | disclosed |
| WO-1990015146-A1 | ENZYMES AND THEIR USE | RHONE-POULENC INC. (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263705-A1 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATES | TSLP, TK1, PTGER3 | PTGS1 445/4885PTGS2 544/4885MAPT 366/4885 |
| US-20090062394-A1 | TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES | TSLP, TK1, PTGER3 | PTGS1 285/4885PTGS2 359/4885MAPT 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.